News | PET-CT | June 20, 2016

PET/CT Imaging of Prostate Cancer Proves Accurate Biopsy Guide

Study shows imaging of prostate-specific membrane antigen leads to highly accurate tumor detection and delineation

prostate cancer, biopsy, PET-CT, Ga-68 PSMA, SNMMI 2016 study, Wolfgang Fendler

June 20, 2016 — Prostate cancer is the leading cancer among men, second only to skin cancer. With surgical removal at the frontline of defense, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and pre-operative planning to root out the full extent of disease, researchers revealed at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Positron emission tomography (PET) and computed tomography (CT) are often used in conjunction to image both the physiological function and structure of recurrent prostate cancer. In recent years, scientists have been developing a PET imaging agent that targets a protein called prostate-specific membrane antigen (PSMA). This protein is over-expressed on the surface of prostate cancer cells and can be detected even after they have spread to other organs. Researchers are able to detect prostate cancer by combining a small amount of radioactive material called gallium-68 and the molecular compound PSMA-HBED-CC (collectively known as Ga-68 PSMA), which is then injected prior to PET/CT scanning. Once administered, the agent binds to cells expressing PSMA and emits a signal detected by the scanner.

Scan images of the tumor data show active tumors glowing like hot coals where they are most virulent. While PSMA PET/CT is not yet the standard of image guidance for biopsies and surgical resection, the findings of this study show that this molecular imaging technique stands to improve tumor staging from the start.

“PSMA shows significant over-expression on prostatic cancer cells and Ga-68 PSMA PET/CT demonstrates a high rate of detection in patients with recurrent, metastatic prostate cancer. However much less research has been conducted for the accuracy of PSMA imaging at the start of the disease,” said Wolfgang P. Fendler, M.D., from the department of nuclear medicine at Ludwig-Maximilians-Universität of Munich in Munich, Germany. “The results of our study indicate that Ga-68 PSMA PET/CT accurately identifies affected regions of the prostate and might thus present a promising tool for non-invasive tumor characterization and biopsy guidance.”

Researchers evaluated subjects with histopathology and maximum standard uptake values using Ga-68 PSMA PET/CT to determine the boundaries of prostate tumor burden in the days prior to surgical resection. Results showed that the 67 percent of segmented tissues that tested positive for cancer via histological evaluation were positively identified by PET/CT via Ga-68 PSMA tumor uptake. With further investigation and regulatory approval, oncologists could one day use prostate-specific molecular imaging to aid needle biopsy and primary staging for better prostate-cancer patient care.

Approximately one out of seven men will be diagnosed with prostate cancer within their lifetime. About 180,890 new cases and 26,120 deaths from prostate cancer are estimated to occur in the U.S. alone in 2016, according to the American Cancer Society.

For more information: www.snmmi.org

Related Content

Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018
March 27, 2018 — While there are many treatment options for men with...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Radiology Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
Overlay Init